Loading organizations...
§ Private Profile · Los Angeles, CA, USA
SpectrumAi is a technology company.
SpectrumAi builds a comprehensive technology platform designed to enhance Applied Behavior Analysis (ABA) therapy for children with Autism Spectrum Disorder. Its core product, Twyll, is a clinical documentation solution that enables ABA providers to efficiently collect and manage data at the point of care. The platform leverages objective data for dynamic visualization through its companion tool, Patterns, providing real-time insights and audit-ready reporting to optimize therapy outcomes.
The company was founded by Ling Shao, whose personal journey as a mother of children diagnosed with ASD illuminated significant systemic challenges in accessing quality ABA services. Drawing upon her extensive background as both a nurse and a healthcare executive, Shao recognized the critical need for a streamlined solution to consolidate provider data and generate actionable analytical insights, leading her to establish SpectrumAi.
SpectrumAi primarily serves ABA providers, empowering them with advanced tools to deliver effective care. The company’s overarching mission is to equip these providers with technology that supports their commitment to quality outcomes, ultimately enabling families across the U.S. to access high-quality care for their children with ASD. Its vision is centered on utilizing objective data to democratize and expand access to best-in-class therapy.
SpectrumAi has raised $29.0M across 2 funding rounds.
SpectrumAi has raised $29.0M in total across 2 funding rounds.
SpectrumAi is a digital health technology company that develops software tools, primarily Twyll—an electronic health record (EHR) system—and Patterns, a data analytics platform, to enhance Applied Behavior Analysis (ABA) therapy for children with autism spectrum disorder (ASD).[1][2][3][5][6] It serves ABA providers like Board Certified Behavior Analysts (BCBAs) and Behavior Technicians (BTs), as well as payers and families, by solving key challenges in real-time data capture, documentation, outcome measurement, and transitioning to value-based care models amid rising insurance coverage and demand for ABA services.[1][3][4][5][6] The company raised up to $20M in Series A funding in 2023 (total funding ~$29M) and demonstrated strong growth momentum before being acquired by CentralReach in 2025.[1][2][4]
SpectrumAi was founded in 2021 in Los Alamitos, California (headquartered near Los Angeles), by Ling, a parent motivated by her own children's ASD diagnoses and frustrations with outdated healthcare tools for tracking therapy quality and outcomes.[1][3] Ling, drawing from personal experience, identified the need for better data consolidation and analytics in ABA therapy, leading her to build a consumer-grade solution for precise, in-the-moment data collection.[3] Early traction came through partnerships with clinical leaders, parents, and payers; the company secured seed investments from F-Prime, Frist Cressey, and Autism Impact Fund, followed by a pivotal 2023 Series A led by CVS Health Ventures (with Cobalt Ventures), fueling Twyll's development and adoption.[1][2][4] This parent-driven origin humanizes SpectrumAi's focus on empowering families and providers with objective insights.[3]
SpectrumAi stands out in the ABA therapy space through purpose-built tools that prioritize real-time, objective data over legacy EHRs, enabling better therapy quality, transparency, and scalability:
These elements position SpectrumAi as a modernizer, helping the industry shift from subjective notes to quantifiable, payer-friendly metrics.[1][5]
SpectrumAi rides the wave of expanding insurance mandates for ABA therapy (e.g., post-ACA growth), where surging demand for autism care collides with outdated tools, creating a ripe market for data-driven digital health innovation.[1][5] Timing aligns with healthtech trends like AI-enabled EHRs and value-based care, amplified by post-pandemic telehealth/hybrid models and payer pressures for outcomes data amid a clinician shortage.[1][2][4] Favorable forces include rising ASD diagnoses (~1 in 36 U.S. children), $2B+ ABA market growth, and investor interest (e.g., CVS Ventures' focus on scalable care).[1][4] By standardizing objective metrics, SpectrumAi influences the ecosystem—boosting ABA efficacy proof, enabling payer contracts, and inspiring peers like Frontera Health—while its 2025 CentralReach acquisition accelerates integration into larger platforms, potentially standardizing data across providers.[1][2]
Post-acquisition by CentralReach in 2025, SpectrumAi's tools will likely scale globally within a leading ABA platform, accelerating AI enhancements for diagnostics, personalized therapy, and payer analytics amid projected 15-20% annual ABA market growth.[1][2][6] Trends like multimodal AI (handling voice/text data) and regulatory pushes for outcomes-based reimbursement will propel Twyll/Patterns, evolving SpectrumAi's influence from innovator to embedded standard in autism care ecosystems.[1][3] As payer scrutiny intensifies, its data flywheel could redefine quality benchmarks, ensuring more families access high-impact ABA—tying back to its parent-fueled mission of timely, evidence-backed therapy.[3]
SpectrumAi has raised $29.0M across 2 funding rounds. Most recently, it raised $20.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $20M Series A | CVS Health | Autism Impact Fund, F Prime Capital, Headwater Ventures, OAK HC/FT, Carl Byers, David Eichler, Carl Bradford Byers 🚑, Navid Farzad | Announced |
| May 1, 2022 | $9M Seed | Carl Bradford Byers 🚑, Navid Farzad | Autism Impact Fund, F Prime Capital, Headwater Ventures, OAK HC/FT, Kent Marquardt | Announced |
SpectrumAi has raised $29.0M in total across 2 funding rounds.
SpectrumAi's investors include CVS Health, Autism Impact Fund, F-Prime Capital Partners, Headwater Ventures, Oak HC/FT, Carl Byers, David Eichler, Carl Bradford Byers 🚑, Navid Farzad, Kent Marquardt.